KR100951396B1 - Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect - Google Patents
Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect Download PDFInfo
- Publication number
- KR100951396B1 KR100951396B1 KR1020030016539A KR20030016539A KR100951396B1 KR 100951396 B1 KR100951396 B1 KR 100951396B1 KR 1020030016539 A KR1020030016539 A KR 1020030016539A KR 20030016539 A KR20030016539 A KR 20030016539A KR 100951396 B1 KR100951396 B1 KR 100951396B1
- Authority
- KR
- South Korea
- Prior art keywords
- toothpaste composition
- granules
- cetylpyridinium chloride
- toothpaste
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000000606 toothpaste Substances 0.000 title claims abstract description 57
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 57
- 206010006326 Breath odour Diseases 0.000 title abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 45
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims abstract description 41
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000551 dentifrice Substances 0.000 claims description 6
- -1 calcium phosphate anhydride Chemical class 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000005498 polishing Methods 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000010677 tea tree oil Substances 0.000 claims description 3
- 229940111630 tea tree oil Drugs 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 241000331120 Krameria cistoidea Species 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229910021536 Zeolite Inorganic materials 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000000576 coating method Methods 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 13
- 230000000845 anti-microbial effect Effects 0.000 abstract description 10
- 230000001629 suppression Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 7
- 230000003239 periodontal effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 239000012676 herbal extract Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 241000186044 Actinomyces viscosus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000010794 food waste Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241001149563 Streptococcus mutans ATCC 25175 Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XQBZDUVLSYARCK-UHFFFAOYSA-J [Mg++].[Ca++].[O-]C([O-])=O.[O-]S([O-])(=O)=O Chemical compound [Mg++].[Ca++].[O-]C([O-])=O.[O-]S([O-])(=O)=O XQBZDUVLSYARCK-UHFFFAOYSA-J 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000006061 abrasive grain Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000007478 blood agar base Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 구취제거, 플라그제거 및 항균효과가 우수한 치약 조성물에 관한 것으로, 구체적으로 염화세틸피리디늄을 연마용 과립입자에 코팅시켜 이를 치약 조성물에 적용한 것을 특징으로 하는 것으로, 본 발명의 치약 조성물은 염화세틸피리디늄을 연마용 과립입자에 코팅시켜 적용하므로서, 이를 구강 적용시 세치하는 동안 안정한 상태로 염화세틸피리디늄을 유지시키고, 또한 치아에 염화세틸피리디늄의 부착을 높여 효능을 지속시킬 뿐만 아니라 타성분과의 안정성 및 치아의 안전성을 기대할 수 있어 구취제거, 항균작용 및 플라그억제능의 효과가 우수하고, 또한 안정성이 높은 안전한 치약 조성물을 제공할 수 있다.
The present invention relates to a toothpaste composition excellent in bad breath removal, plaque removal and antimicrobial effect, and in particular, to the toothpaste composition characterized in that the coating of the cetylpyridinium chloride to the abrasive granules, By applying cetylpyridinium chloride to the abrasive granules, it maintains cetylpyridinium chloride in a stable state during the oral application, and also increases the adhesion of cetylpyridinium chloride to the teeth to maintain efficacy. It can be expected that the stability with other components and the safety of teeth can be excellent in the effects of bad breath removal, antibacterial action and plaque suppression, and can provide a safe toothpaste composition with high stability.
염화세틸피리디늄, 치약, 조성물, 과립, 코팅.Cetylpyridinium chloride, toothpaste, composition, granule, coating.
Description
본 발명은 구취제거, 플라그제거 및 항균효과가 우수한 치약 조성물에 관한 것으로, 구체적으로 염화세틸피리디늄을 연마용 과립입자에 코팅시켜 이를 적용한 치약 조성물에 관한 것이다.
The present invention relates to a toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect, and more particularly, to a toothpaste composition to which the cetylpyridinium chloride is coated on the abrasive grains.
구취는 구강내 황함유물질의 존재, 위 또는 폐의 질병 및 타액분비의 부족을 우선하여 구강내 음식잔사의 존재, 플라그의 존재 및 치주조직의 염증 등으로 인해 발생하는 것으로, 이러한 구취는 대인관계에서 문제가 된다.Bad breath is caused by the presence of food residues in the oral cavity, the presence of plaque and inflammation of the periodontal tissues in preference to the presence of sulfur-containing substances in the oral cavity, diseases of the stomach or lungs, and lack of salivary secretion. Is a problem.
상기 구취의 원인 중 하나인 플라그는 치구 또는 치태라 불리는 것으로, 구강내의 박테리아 및 그 부산물과 음식 찌꺼기로 치면에 고착되어 치밀하고 겔과 같은 미생물의 기질로 석회화되기 전의 덩어리를 말한다. 이러한 플라그는 석회화로 인해 치석이 형성되고, 또한 염증성 치주병을 일으키는 원인이 되어 구강질환에서 가장 중요한 인자로 인식되고 있다. Plaque, which is one of the causes of bad breath, is called plaque or plaque, and refers to a lump before it is adhered to the tooth surface by bacteria and its by-products and food residues in the oral cavity, before being calcified into a dense and microorganism such as a gel. These plaques are formed by calcareous calculus and cause inflammatory periodontal disease, which is recognized as the most important factor in oral diseases.
따라서, 플라그 및 이로 인한 염증에 대한 관리는 구강관리에 있어 가장 필수적인 요소라 해도 과언이 아니다. 이에 플라그검사는 구강상태 및 건강상태에 있어 가장 중요한 검사항목으로, 플라그 조절없이 치주치료는 성립되지 않는다.
Therefore, the management of plaque and the resulting inflammation is not an exaggeration to say that it is the most essential element in oral care. The plaque test is the most important test item in the oral condition and health status, periodontal treatment is not established without plaque control.
이러한 플라그에 대한 억제능이 우수하며 높은 항균력으로 의약품 및 의약외품의 구강액 및 세치제에 빈용되는 염화세틸피리디늄은 그 효능의 인정과 그 우수한 안정성 및 안전성으로 최근 고시품목으로 설정되었다[2000년 기준 및 시험방법 제2개정 추보1].Cetylpyridinium chloride, which has excellent inhibitory ability against plaque and is frequently used in oral fluids and dentifrices of medicines and quasi-drugs with high antibacterial activity, has recently been set as a public notice item because of its recognition of its efficacy and its excellent stability and safety [2000 standards and Test Method 2 Amendment 1].
염화세틸피리디늄(Cetylpyridinium Chloride, 이하 "CPC"라 칭함)은 치석을 억제하는데 유용한 양이온성 항균제로서, 기타 유사한 항균제들이 갖는 치아착색 등의 부작용이 적은 특징이 있으나, 구강내에서 빨리 분해가 일어나 효능이 지속적이지 못한 단점이 있다. 구체적으로 CPC는 양이온을 띄고 있으면서 치면 세균막이나 타액 단백질과 공유결합을 함으로써 치석을 억제하며 타액내 세균에 대한 항균작용을 나타내는데, 이러한 시험관내(in vitro) 실험에서의 결과에 비해 임상에서의 항균 및 치은염에 대한 결과는 만족스럽지 못한 것으로 나타난다[J. Oral Rehabilitation 1985, 12, 81; J. Clinical Periodontology 1988, 15, 488]. 이것은 CPC가 뛰어난 항균효과를 지녔고 구강 조직에 빠르게 부착되는데도 불구하고 구강 조직에서 빠르게 분해되어 그 작용이 오랜 기간 동안 지속될 수가 없기 때문이다. 이러한 이유로 염화세틸피리디늄은 그 우수한 효과를 나타남에도 그 사용이 제한적이다. Cetylpyridinium Chloride (hereinafter referred to as "CPC") is a cationic antimicrobial agent useful for inhibiting calculus. There is a disadvantage that is not persistent. Specifically, CPC suppresses tartar by covalently binding to bacterial membranes or saliva proteins while having a cation, and exhibits antimicrobial activity against bacteria in saliva, compared with the results of in vitro experiments. The results for gingivitis appear to be unsatisfactory [ J. Oral Rehabilitation 1985, 12, 81; J. Clinical Periodontology 1988, 15, 488]. This is because CPC has an excellent antimicrobial effect and rapidly decomposes in the oral tissues even though they adhere quickly to the oral tissues, and the action cannot be continued for a long time. For this reason, cetylpyridinium chloride is limited in its use despite its excellent effect.
종래, CPC를 함유시켜 일반 치약 조성물로 단순히 구성하는 것(국제공개특허 94-700051)이나 CPC를 분말로서 적용시키는 예(대한치주과학회지 1999, 29, 1, p144)가 보고되었으나, 단순히 구성하는 경우 CPC의 빠른 분해로 인해 그 효능이 지속적이지 못하며, 또한 분말로서 적용시 CPC 자체의 치아에 마모 및 자극 등의 역작용이 우려되고 있다.In the related art, a simple composition of a general toothpaste composition containing CPC (International Patent Publication No. 94-700051) or an example of applying CPC as a powder (Korean Journal of Periodontal Medicine 1999, 29, 1, p144) has been reported. Due to the rapid decomposition of CPC, its efficacy is not sustained, and when applied as a powder, there is a concern about adverse effects such as wear and irritation on the teeth of the CPC itself.
이에, 그 효과가 우수한 염화세틸피리디늄을 치아에 적용시 지속적인 효능의 증강 뿐 아니라 치아의 안정성을 고려한 적극적인 방법이 요구되고 있다.
Therefore, there is a need for an active method considering the stability of the tooth as well as the continuous enhancement of the effect when applying the cetylpyridinium chloride excellent in the effect.
본 발명은 상기한 문제점을 해결하기 위한 것으로, 염화세틸피리디늄을 과립에 코팅시켜 그 안정성을 상승시키고 제품에 적용시 그 효과를 극대화시킬 수 있는 치약 조성물을 제공하는 것이다.
The present invention is to solve the above problems, it is to provide a toothpaste composition that can be coated on the granules of cetylpyridinium chloride to increase its stability and maximize the effect when applied to the product.
상기한 목적을 달성하기 위하여, 본 발명은 치약 조성물에 있어서, 과립 표면에 염화세틸피리디늄이 코팅된 것을 유효성분으로 하는 치약 조성물을 제공한다.In order to achieve the above object, the present invention provides a toothpaste composition in the toothpaste composition, which is coated with cetylpyridinium chloride on the surface of the granules as an active ingredient.
즉, 염화세틸피리디늄을 과립표면에 코팅제를 이용하여 코팅시켜 치약 조성물에 적용하므로서, 치약 조성물에 염화세틸피리디늄의 지속적인 항균작용과 과립의 물리적 특성을 부여하고, 이로인해 양치시 치간사이의 세세한 부분까지 플라그 억제효과를 강화할 수 있어 구취제거, 플라그제거 및 항균효과를 나타내는 것을 특 징으로 한다.
In other words, by applying the coating on the surface of the granules of cetylpyridinium chloride with a coating agent, the toothpaste composition to the continuous antimicrobial action and physical properties of the granules to the toothpaste composition, thereby giving It can enhance the plaque suppression effect to the part, and it is characterized by showing bad breath removal, plaque removal and antibacterial effect.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 치약 조성물을 구성함에 있어서, 본 발명의 특징은 염화세틸피리디늄을 코팅제를 이용하여 과립표면에 코팅한 것을 적용하는 것이다.In constructing the toothpaste composition of the present invention, a feature of the present invention is to apply the coating of the surface of the granules with cetylpyridinium chloride using a coating agent.
염화세틸피리디늄은 치석을 억제하는데 유용한 양이온성 항균제로서, 기타 유사한 항균제들이 갖는 치아착색 등의 부작용이 적은 특징이 있다. 구체적으로 양이온을 띄고 있으면서 치면 세균막이나 타액 단백질과 공유결합을 함으로써 치석을 억제하며 타액내 세균에 대한 항균작용을 나타낸다. 염화세틸피리디늄은 본 발명에서 치약 조성물의 유효성분 중 하나로 함유하며, 이때 함량은 전체조성물에 대하여 0.01∼5 중량%가 바람직하다.
Cetylpyridinium chloride is a cationic antimicrobial agent useful for inhibiting calculus and is characterized by fewer side effects such as tooth staining of other similar antimicrobial agents. Specifically, while having a cation, covalent bonds with bacterial membranes or saliva proteins inhibits calculus and shows antimicrobial activity against bacteria in saliva. Cetylpyridinium chloride is contained as one of the active ingredients of the toothpaste composition in the present invention, the content is preferably 0.01 to 5% by weight based on the total composition.
본 발명에서 과립은 그 표면에 염화세틸피리디늄을 코팅시켜 염화세틸피리디늄의 안정성을 향상시키는 약물전달체로서의 역할을 수행하며, 또한 과립 자체의 물리적 특성을 부여하여 양치시 치간사이의 세세한 부분까지 플라그 억제효과를 강화할 수 있는 특징을 나타낸다.In the present invention, the granules serve as drug carriers to improve the stability of cetylpyridinium chloride by coating cetylpyridinium chloride on the surface thereof, and also to impart the physical properties of the granules themselves to plaque to the minute parts between the interdental teeth. It exhibits features that can enhance the inhibitory effect.
상기 과립은 제조공정 및 소비자의 입안 감촉(Mouth feel) 및 치약내 적용시의 안정성을 고려하여 적절한 크기와 강도를 규정해야 한다. 구체적으로, 과립의 강도가 너무 높으면 치아에 무리를 주어 치아표면에 손상을 줄 수 있으며, 과립의 강도가 약하면 치약제조 공정시 파괴되어 과립으로서 의미를 잃을 수 있다. 따라 서 과립의 강도는 제조공정에서 파괴되지 않고 양치시 파괴되는 정도인 과립의 강도는 150∼650 g/㎠가 적당하다. 또한, 과립의 크기는 100∼750 ㎛가 적당하다. 상기 크기는 사용시 이물감으로 느끼지 않으면서 양호한 사용감을 갖는 크기이다.The granules should be defined in appropriate size and strength in consideration of the manufacturing process, the mouth feel of the consumer, and the stability in application in the toothpaste. Specifically, if the strength of the granules is too high, it may damage the tooth surface by imparting the teeth, and if the strength of the granules is weak, the granules may be destroyed during the toothpaste manufacturing process and lose meaning as granules. Therefore, the strength of the granules, which are not destroyed in the manufacturing process but destroyed when brushing, is suitably 150-650 g / cm 2. In addition, the size of the granules is suitable from 100 to 750 ㎛. The size is a size having a good feeling without feeling a foreign object in use.
또한, 상기 과립은 연마제가 유익하며, 과립화하여 유통되는 가능한 연마제로는 침강탄산칼슘, 실리카, 제오라이트, 클로이드성 이산화규소 및 무수인산칼슘 등을 사용할 수 있다.In addition, the granules are beneficial to abrasives, and precipitated calcium carbonate, silica, zeolite, clad silicon dioxide and calcium phosphate anhydride may be used as possible abrasives that are granulated and distributed.
상기 과립은 본 발명에서 치약 조성물의 유효성분으로 함유하며, 이때 함량은 전체조성물에 대하여 0.1∼10 중량%가 바람직하다.
The granules are contained as an active ingredient of the toothpaste composition in the present invention, wherein the content is preferably 0.1 to 10% by weight based on the total composition.
본 발명의 코팅은 코팅제를 이용하여 수행되며, 상기 코팅제는 염화세틸피리디늄을 과립 표면에 코팅시 사용되는 것으로, 치약 조성물에 안정하게 함유되어 구강내에 적용하였을 때 염화세틸피리디늄을 용이하게 방출할 수 있고 구강내에서 쉽게 파괴될 수 있는 물질이 바람직하다. 본 발명에서는 수용성 고분자물질로서 높은 안정성으로 약제학적 응용에 빈용되는 물질을 사용하며, 구체적으로 폴리에틸렌글리콜, 메틸셀룰로스, 히드록시프로필셀룰로스, 히드록시프로필메틸셀룰로스, 에틸셀룰로스, 히드록시셀룰로스, 폴리비닐알콜, 폴리비닐피롤리돈 및 기타 왁스류 등으로 이루어진 군에서 선택된 1 종 이상을 사용한다. 또한, 타액 및 타액에 존재하는 효소에 의해 분해가 가능한 물질도 사용할 수 있다.The coating of the present invention is carried out using a coating agent, and the coating agent is used to coat cetylpyridinium chloride on the surface of the granules, which is stably contained in the dentifrice composition to easily release cetylpyridinium chloride when applied in the oral cavity. Preferred are materials that can be and easily destroyed in the oral cavity. In the present invention, as a water-soluble high molecular material, a substance that is poorly used in pharmaceutical applications with high stability is used, and specifically, polyethylene glycol, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hydroxy cellulose, polyvinyl alcohol , At least one selected from the group consisting of polyvinylpyrrolidone and other waxes. In addition, saliva and substances that can be degraded by enzymes present in saliva can also be used.
염화세틸피리디늄을 코팅제를 이용하여 과립 표면에 코팅하는 방법은 본 분야에서 알려진 통상적인 모든 방법을 사용할 수 있다. 일예로, 유동층조립기를 이 용한 코팅방법과 침적법을 이용한 코팅방법이 있다. 상기 유도층 조립기를 이용한 코팅방법은 코팅제와 과립을 혼합시킨 후 유동층조립기를 이용하여 과립을 띄운 후 용액을 서서히 뿌리는 방법으로 코팅한다. 코팅 후 건조과정을 통하여 용매를 제거한 후 적당한 체에 걸러 용매를 완전히 제거한고 분배를 고르게 한다. 또한, 침적법(deeping method)을 이용한 코팅방법은 과립을 침지시킬 때 침적용매 및 과립의 성질을 고려하여 적절한 농도 및 조건을 잡아 주어여 한다.
The method of coating the surface of granules with cetylpyridinium chloride using a coating agent can use all conventional methods known in the art. For example, there is a coating method using a fluidized bed granulator and a coating method using a deposition method. In the coating method using the induction layer granulator, the coating agent and the granules are mixed, and the granules are floated using the fluidized bed granulator. After coating, the solvent is removed through a drying process, and then filtered through a suitable sieve to completely remove the solvent and evenly distribute the solvent. In addition, the coating method using the deeping method should be given the appropriate concentration and conditions in consideration of the properties of the deposition solvent and granules when immersing the granules.
또한, 본 발명의 치약 조성물은 유효성분으로 염화세틸피리디늄 및 과립을 함유한 치약 조성물에 추가로 생약추출물을 함유한다. 상기 생약추출물은 티트리오일(Tea tree oil), 자소추출물, 캄모밀(Chamomile), 라타니아(Rathania), 미르(Myrr) 및 솔잎추출물이다. 상기 생약추출물은 플라보노이드를 함유하여 항염 및 혈행촉진 등의 효능을 나타내는 것으로, 이를 치약 조성물에 추가로 함유시키므로, 본 발명에서 목적한 효능에 상승적인 활성을 제공한다. 상기 생약추출물의 함유량은 치약 조성물 100 중량%에 대하여 0.01∼10 중량부가 바람직하다.
In addition, the toothpaste composition of the present invention contains the herbal extract in addition to the toothpaste composition containing cetylpyridinium chloride and granules as an active ingredient. The herbal extracts are tea tree oil, tea extract, chamomile, ratania, myrr and pine needle extract. The herbal extracts contain flavonoids to show the efficacy of anti-inflammatory and blood circulation, and further include them in the toothpaste composition, thereby providing synergistic activity to the desired efficacy in the present invention. The content of the herbal extract is preferably 0.01 to 10 parts by weight based on 100% by weight of the toothpaste composition.
또한, 본 발명의 치약 조성물은 통상적으로 점결제, 보습제, 기포제, 감미료 및 향미제 성분을 함유한다. 특히, 본 발명에서 과립을 연마용 과립으로 사용하므로서 통상적으로 포함되는 연마제의 함량을 감소시키거나 사용하지 않을 수 있다.In addition, the toothpaste composition of the present invention usually contains a caking additive, a humectant, a foaming agent, a sweetener and a flavoring component. In particular, in the present invention, by using the granules as polishing granules, it is possible to reduce or not use the amount of abrasives usually included.
연마제는 치아의 세척 및 광택을 유지시키는 것으로, 제2인산칼슘 2수화물 및 무수물, 제2인산칼슘, 탄산칼슘, 피로인산칼슘, 수산화알루미늄, 무수규산, 규 산알루미늄, 불용성 메타인산나트륨, 제3인산마그네슘, 탄산마그네슘황산칼슘, 포리메타아크릴산메틸 및 기타 합성 수지 등에서 선택된 1 종 이상을 함유한다.Abrasives are to maintain the cleaning and gloss of teeth, dicalcium phosphate dihydrate and anhydride, dicalcium phosphate, calcium carbonate, calcium pyrophosphate, aluminum hydroxide, silicic anhydride, aluminum silicate, insoluble sodium metaphosphate, tertiary It contains one or more selected from magnesium phosphate, magnesium carbonate calcium sulfate, methyl polymethacrylate, and other synthetic resins.
결합제는 고체인 분말성분과 액체성분이 분리되지 않게 해주는 역할을 하는 것으로, 연고상의 치약에서는 필수적인 것으로 임의의 수용성 고분자를 사용할 수 있다. 구체적으로 나무의 셀룰로스로부터 합성된 카르복시메틸셀룰로스 나트륨, 해조류로부터 추출된 카라기난류 및 미생대사로부터 얻어진 잔탄검 카보플 및 이의 혼합물 등을 들 사용할 수 있다.The binder serves to prevent the solid powder component and the liquid component from being separated, and is essential for the ointment toothpaste, and any water-soluble polymer may be used. Specifically, sodium carboxymethylcellulose synthesized from cellulose of trees, carrageenans extracted from seaweeds and xanthan gum carboples obtained from microorganisms and mixtures thereof may be used.
보습제는 솔비톨, 글리세린, 농글리세린, 자일리톨, 에틸렌글리콜, 프로필렌글리콜, 폴리에틸렌글리콜, 폴리프로필렌글리콜 및 이들의 혼합물을 사용한다.Moisturizing agents use sorbitol, glycerin, concentrated glycerin, xylitol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol and mixtures thereof.
기포제는 제품의 사용감을 증진시키고 세정작용을 도와주며, 기타 약효성분의 분산 및 침투를 신속하게 하고 계면장력을 감소시킴으로서 구강내 이물질이 쉽게 떨어지게 하는 작용을 한다. 기포제로는 주로 음이온성 계면활성제인 라우릴황산나트륨이 사용되며, 제형의 특성에 따라 보조적으로 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴록사머), 폴리옥시에틸렌 경화 피마자유, 폴리옥시에틸렌솔비탄 지방산 에스테르 등이 사용될 수 있다.Foaming agent enhances the feeling of use of the product, helps cleansing action, and facilitates the dissolution of foreign substances in the oral cavity by speeding up the dispersion and penetration of other active ingredients and reducing the interfacial tension. As the foaming agent, sodium lauryl sulfate, an anionic surfactant, is mainly used, and a copolymer of polyoxyethylene polyoxypropylene (poloxamer), polyoxyethylene cured castor oil, poly Oxyethylene sorbitan fatty acid ester and the like can be used.
또한, 기타 약효성분을 함유할 수 있는데, 대표적으로 불화물이 있으며, 불소이온소스로 불화나트륨, 불화인산나트륨을 단독 또는 혼합사용할 수 있다. 치주질환 예방을 목적으로 높은 삼투압을 가지는 염화나트륨이나 탄산수소나트륨 등의 수용성염과 지혈작용을 갖는 아미노카프론산, 알란토인, 알란토인의 유도체와 여러 가지 비타민류를 동시에 사용할 수 있다. In addition, it may contain other active ingredients, typically fluoride, sodium fluoride, sodium fluoride phosphate may be used alone or mixed as a fluorine ion source. For the purpose of preventing periodontal disease, water-soluble salts such as sodium chloride or sodium bicarbonate with high osmotic pressure, aminocapronic acid, allantoin, and allantoin derivatives having hemostatic action and various vitamins can be used simultaneously.
기타 본 발명의 치약 조성물은 사용감을 좋게 하기 위하여 향료, 감미료, 식용색소류 및 식향료가 사용되며, 메톨, 아네톨, 유칼립톨, 티몰, 페파민트오일, 스피아민트오일, 세이지, 메틸살리실레이트 및 과일추출물 등을 사용할 수 있다.Other toothpaste compositions of the present invention are used for flavoring, sweetening, food coloring and flavoring to improve the feeling, metol, anetol, eucalyptol, thymol, peppermint oil, spearmint oil, sage, methyl salicylate and Fruit extracts can be used.
통상적인 치약 조성물은 하기와 같은 구성비로 구성된다.Conventional toothpaste compositions consist of the following ratios.
이하, 본 발명을 실시예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의하여 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited by the following examples.
<제조예 1∼4> 과립에 염화세틸피리디늄의 코팅Preparation Examples 1 to 4 Coating of Cetylpyridinium Chloride on Granules
과립은 SiO2를 사용하였고(Sorbosil BFG50, 영국Ineos사), 수회의 예비실험을 통해 용매를 물:에탄올 혼합용매 또는 물을 사용하였으며, 코팅방법은 유동층 조립기를 이용한 코팅방법을 사용하였다. 구체적인 구성성분 및 함량은 하기 표 2에 나타내었다.The granules were SiO 2 (Sorbosil BFG50, Ineos, UK), and the solvent was used as a water: ethanol mixed solvent or water through several preliminary experiments, and the coating method was a coating method using a fluidized bed granulator. Specific components and contents are shown in Table 2 below.
코팅 조건은 하기와 같이 조작하였다.Coating conditions were operated as follows.
유동층 조립기는 FREUND사의 FIF200을 사용하였으며, 하기와 같은 조건으로 코팅을 수행하였다.Fluid bed granulator was used FIFUND FIF200, coating was carried out under the following conditions.
<유동층 조립기 운전조건><Operating Bed Assembly Condition>
(1) 작업전 집진장치를 가동한다(1) Start dust collector before work
(2) 혼합시간 : 60℃에서 20분(원료건조 병행)(2) Mixing time: 20 minutes at 60 ° C (raw material drying in parallel)
(3) Out Let Damp : 과립개시 1단 →이후 3단(3) Out Let Damp: granule start 1 stage → after 3 stage
(4) In Let Damp : 과립개시 3단 →이후 6단(4) In Let Damp: granule start 3 steps → after 6 steps
(5) 스프레이 속도 : 400∼500 ㎖/분(평균=450 ㎖/분)(5) Spray rate: 400 to 500 ml / min (average = 450 ml / min)
(6) 건조 온도 : 70 →65℃(6) Drying temperature: 70 → 65 ℃
(7) 스프에이 온도 : 3 ㎏/㎠(7) soup temperature: 3 kg / ㎠
(8) 스팀압 : 3 ㎏/㎠(8) Steam pressure: 3 kg / ㎠
(9) 압축공기공급원 : 6 ㎏/㎠(9) Compressed air source: 6 ㎏ / ㎠
(10) 스프레이 에어압 : 4 ㎏/㎠
(10) Spray air pressure: 4 kg / ㎠
상기 표 2에서 보는 바와 같이, 과립에 함유하는 염화세틸피리디늄 농도의 차이를 두어 코팅하고 수율을 계산한 결과, 평균 99.3 %의 높은 수율을 얻을 수 있었으며, 용매의 차이는 나타나지 않았으며 제조후 상태도 양호하고 입자 크기도 100∼700 ㎛으로 구성되었다.
As shown in Table 2 , the coating yields a difference in the concentration of cetylpyridinium chloride contained in the granules, and as a result, a high yield of 99.3% was obtained, and no difference was found between solvents. It is also good and the particle size is composed of 100 ~ 700 ㎛.
<실시예 1∼2> 본 발명의 치약 조성물의 제조<Examples 1-2> Preparation of the toothpaste composition of this invention
습윤제에 결합제 및 기타 첨가제 등을 미리 분산하고, 연마제 및 항치석제 등 약효성 성분을 투입한 후 약 30 분간 교반하였다.Binder and other additives were previously dispersed in the humectant, and weakly active ingredients such as an abrasive and an anti-tartar was added, followed by stirring for about 30 minutes.
마지막으로 기포제와 향료제를 투입한 후 진공상태에서 20 분간 교반시켜 본 발명의 치약 조성물을 제조하였다.Finally, the foaming agent and the flavoring agent were added, followed by stirring for 20 minutes in a vacuum to prepare a toothpaste composition of the present invention.
또한, 동일한 방법으로 본 발명의 치약 조성물과 비교하기 위하여 기존 치약 조성물을 제조하여 이를 비교예로 사용하였다.In addition, in order to compare the toothpaste composition of the present invention in the same way to prepare a conventional toothpaste composition was used as a comparative example.
각 첨가되는 성분 및 조성비는 하기 표 3에 나타낸 바와 같다.
Each added component and composition ratio are as Table 3 below.
<비교예 1∼3> 치약 조성물의 제조<Comparative Examples 1 to 3> Preparation of Toothpaste Composition
하기 표 3에 나타낸 바와 같이, 각 첨가되는 성분을 조성비에 따라 상기 실시예와 동일한 방법으로 제조하였다.As shown in Table 3 below, each added component was prepared in the same manner as in the above Example according to the composition ratio.
<실험예 1> 치약 조성물의 안정성 실험Experimental Example 1 Stability Experiment of Toothpaste Composition
상기 실시예 및 비교예에 의해 제조된 치약 조성물의 안정성을 확인하게 위하여 실험을 수행하였다.Experiments were conducted to confirm the stability of the dentifrice compositions prepared by the examples and comparative examples.
각각의 치약 조성물을 각각 30℃, 40℃ 및 50℃의 항온조에서 12 주 동안 보관한 후 치약 조성물의 물리적 안정성을 관찰하였다. 결과는 하기 표 4에 나타내었다.Each toothpaste composition was stored in a thermostat at 30 ° C., 40 ° C. and 50 ° C. for 12 weeks, and then the physical stability of the toothpaste composition was observed. The results are shown in Table 4 below.
상기 표 4에서 보는 바와 같이, 본 발명의 실시예 1 및 2는 0∼50℃의 온도에서 안정함을 나타내고 있으나, 비교예에서는 약 7 주후 탈색 및 조성물의 분말성분과 액체성분이 분리되는 현상이 나타남을 알 수 있다. 그러나, 비교예 3의 경우 안정한 것을 나타나고 있다. 이를 통하여 염화세틸피리디늄 자체를 함유한 치약 조성물은 염화세틸피리디늄을 함유하지 않은 치약 조성물(비교예 3)보다 더욱 안정성이 떨어짐을 알 수 있으며, 본 발명과 같이 염화세틸피리디늄을 과립에 코팅하여 함유시켰을 경우, 치약 조성물의 안정성이 향상됨을 알 수 있엇다.
As shown in Table 4 , Examples 1 and 2 of the present invention shows a stable at a temperature of 0 ~ 50 ℃, in the comparative example after 7 weeks decolorization and the phenomenon that the powder and liquid components of the composition is separated It can be seen that. However, in the case of Comparative Example 3, it is shown that it is stable. Through this, it can be seen that the toothpaste composition containing cetylpyridinium chloride itself is less stable than the toothpaste composition containing no cetylpyridinium chloride (Comparative Example 3), and coated the granules with cetylpyridinium chloride as in the present invention. When included, it can be seen that the stability of the toothpaste composition is improved.
<실험예 2> PCR 및 RDA의 측정Experimental Example 2 Measurement of PCR and RDA
본 발명의 치약 조성물의 세정능력 및 연마력을 알아보기 위하여 통상적인 지방막세정비율(PCR, Pellicle Cleaning Ratio) 및 방사능상아질 연마(RDA, Radioactive Dentine Abrasivity) 값을 측정하였다. 결과는 하기 표 5에 나타내었다.In order to determine the cleaning ability and polishing power of the toothpaste composition of the present invention, the conventional fat cleaning ratio (PCR) and radioactive dentine abrasion (RDA) values were measured. The results are shown in Table 5 below.
상기 표 5에서 보는 바와 같이, 본 발명의 실시예 1 및 2에서 PCR 값이 높게 나타났고, RDA값은 모든 비슷한 정도의 값을 나타내었다. 이는 과립을 함유하고 있다고 해서 연마력이 높아진다기 보다 세정력이 우수한 것을 평가되는 것으로, 즉 과립이 치간부분까지 염화세틸피리디늄을 전달해 줌으로써 과립자체의 연마력보다는 전달된 염화세틸피리디늄의 세정력이 높아지는 것으로 사료된다.
As shown in Table 5 , the PCR values were high in Examples 1 and 2 of the present invention, and the RDA values showed all similar values. This means that the granules contain better cleaning power rather than higher polishing power, that is, the granules transfer cetylpyridinium chloride to the interdental area, thereby increasing the cleaning power of the transferred cetylpyridinium chloride rather than the abrasiveness of the granule itself. do.
<실험예 3> MIC 측정Experimental Example 3 MIC Measurement
본 발명의 치약 조성물에 대한 충지균과 치주질환 원인균에 대한 항균작용을 알아보기 위해 MIC 측정을 수행하였다.MIC measurement was carried out to determine the antimicrobial activity against the fungus and causative agent of periodontal disease on the toothpaste composition of the present invention.
CPC를 농도별로 함유한 Brain heart Infusion agar(BHIA)를 사용하여 한천배지 희석법으로 항균력을 평가하였다. 치주질환원인균의 경우, 37℃, 5 % CO2 조건하에서 5일간 배양하였고, 충치원인균의 경우, 37℃, 호기성 조건하에서 2일간 배양한 후 세균의 발육을 억제하는 최소농도를 최소발육억제농도(MIC)로 결정하였다.Brain heart infusion agar (BHIA) containing CPC concentration was used to evaluate the antimicrobial activity by agar medium dilution method. The periodontal pathogens were cultured for 5 days at 37 ° C. and 5% CO 2. For caries, they were cultured at 37 ° C. for 2 days under aerobic conditions. MIC).
또한 실시예 1 및 비교예 3을 농도별로 함유한 BHIA를 사용하여 한천배지 희석법으로 항균력을 평가하였다. 시험농도는 시험치약의 50배 희석농도(10 ㎍/㎖)부터 2배씩 희석하여 총 10 단계의 희석농도에서 수행하였다.In addition, the antibacterial activity was evaluated by agar medium dilution method using BHIA containing Example 1 and Comparative Example 3 by concentration. The test concentration was diluted twice from the 50-fold dilution concentration (10 ㎍ / ㎖) of the test toothpaste was carried out in a total dilution concentration of 10 steps.
결과는 하기 표 6에 나타내었다.The results are shown in Table 6 below.
(1) 시험균(1) Test bacteria
① 치주질환원인균 : 액션바실러스 액티노마이세템코미탄스(Actionbacilus Actinomycetemcomitans ATCC 29522), 후소박테리움 뉴클레아툼(Fusobacterium nucleatum ATCC 25586).① Periodontal pathogens: Actionbacilus Actinomycetemcomitans ATCC 29522, Fusobacterium nucleatum ATCC 25586.
② 충치원인균 : 스트렙토코커스 뮤탄스(Streptococcus mutans ATCC 25175), 액티노마이시스 비스코서스(Actinomyces viscosus ATCC 158987).② caries cause: Streptococcus mutans ATCC 25175, Actinomyces viscosus ATCC 158987.
(2) 사용배지(2) medium used
혈액한천배지(혈액한천 베이스 + 최종농도 5 %의 양 혈액) BHI 한천Blood agar medium (blood agar base + final volume 5% blood) BHI agar
상기 표 6에서 보는 바와 같이, 각 시험균에 항균력을 나타내기 위한 MIC가 0.5∼8 ㎍/㎖로 나타났으며, 본 발명의 실시예 1은 비교예 3에 비해 실험균주에 있어 각각 평균 2 배 정도의 항균력을 나타내고 있어 본 발명의 치약 조성물이 포함하고 있는 염화세틸피리디늄 코팅된 과립에서의 염화세틸피리디늄의 용출이 원활하고 우수한 항균성을 나타내고 있음을 알 수 있다.
As shown in Table 6 , the MIC for showing the antimicrobial activity to each test bacterium was found to be 0.5 ~ 8 ㎍ / ㎖, Example 1 of the present invention compared to Comparative Example 3 in the experimental strain, respectively, on average 2 times The degree of antimicrobial activity is shown, and it can be seen that the elution of cetylpyridinium chloride in the cetylpyridinium chloride coated granules contained in the toothpaste composition of the present invention is smooth and shows excellent antimicrobial activity.
<실험예 4> 치약 조성물의 구취제거 효과 측정Experimental Example 4 Measurement of Bad Breath Removal Effect of Toothpaste Composition
본 발며의 치약 조성물에 대해서 구취제거 효과를 알아보기 위하여, 평상시에 구취가 있다고 자각하고 있는 60 여명의 임상적 실험 대상자를 모집한 후 동일한 식사를 먹게 하고 통상적인 할리메타를 이용하여 구취의 정도를 정량화하였다.In order to find out the effect of removing bad breath on the toothpaste composition, we recruited about 60 clinical subjects who perceived bad breath as usual, and then ate the same meal. Quantification.
구취가 약하거나 아주 강한 사람을 실험대상에서 제외시킨 후 각 조성물군 당 10명씩 분배하여 평균값이 각 군간에 비슷하게 되도록 조절하였다. 다음날 동일한 방법으로 실험값의 재현성을 확인한 후 동일한 식사와 간식을 먹게 하고, 1 시간 후 초기 구취정도를 측정하고 나서 각 조성물군 별로 동일방법과 시간으로 양치시킨 후 1 시간 경과 후 말기 구취정도 및 PCR 값을 측정하였다. 양치 전과 후의 할리메타 수치의 차이를 구하고 그룹별로 평균값을 비교하였다. 결과는 표 7에 나타내었다.Weak or very strong people with bad breath were excluded from the test subjects and each group was divided into 10 groups to adjust the average value to be similar between each group. The next day, after confirming the reproducibility of the experimental value, the same meal and snacks were eaten, and after 1 hour, the initial bad breath was measured, and after each hour, each group was brushed with the same method and time. Was measured. Differences in the Harimetta value before and after brushing were obtained and the mean value was compared for each group. The results are shown in Table 7 .
상기 표 7에서 보는 바와 같이, 본 발명의 치약 조성물 및 염화세틸피리디늄을 함유한 비교예 1 및 2의 치약 조성물이 구취효과가 우수함을 알 수 있었다. 특히, 본 발명의 치약 조성물은 일반적으로 염화세틸피리디늄을 함유한 것(비교예 1 및 2) 보다 더욱 구취효과가 나타남을 확인할 수 있었다.
As shown in Table 7 , it was found that the toothpaste compositions of Comparative Examples 1 and 2 containing the toothpaste composition and cetylpyridinium chloride of the present invention had an excellent bad breath effect. In particular, it was confirmed that the toothpaste composition of the present invention exhibited a more bad breath effect than those containing generally cetylpyridinium chloride (Comparative Examples 1 and 2).
<실험예 5> 플라그 검사 PCRExperimental Example 5 Plaque Test PCR
플라그검사는 구강상태 및 건강상태에 있어 가장 중요한 검사항목으로서, 플라그 조절(control)없이 치주치료는 성립되지 않는다.Plaque test is the most important test item for oral condition and health condition, and periodontal treatment is not established without plaque control.
육안으로 플라그의 부착상태를 판정하기 어렵기 때문에 염색을 해서 판정하였다. 염색제는 주로 에리드로신(erythrosin)을 주제로한 것으로 염색액을 면구에 적셔서 치아의 표면에 도포하였다. 양치 후 염색된 플라그의 부착지면을 산정하였다. 플라그 부착을 나타내는 지수로서 일상적인 임상에서 흔히 사용되고 있는 O'Leary의 Plaque Control Record(PCR)은 치면을 4면(협측, 설측, 근심측, 원심측)으로 구분하고 염색된 면의 수를 산정하였다(치주과학 교문사, 남용옥저). 결과는 하기 표 8에 나타내었다.Since it was difficult to visually determine the adherence state of the plaque, the staining was performed. The dye was mainly erythrosin-based, and the dye was applied to the surface of the teeth by moistening the dye solution in a cotton ball. After brushing, the adhesion surface of the stained plaque was calculated. O'Leary's Plaque Control Record (PCR), which is commonly used in daily clinical practice as an index indicating plaque adhesion, divided the tooth surface into four sides (buccal, lingual, mesial, and distal) and calculated the number of stained surfaces. (President of Periodontal Science, Nam Yong Ok). The results are shown in Table 8 below.
상기 표 8에서 보는 바와 같이, 본 발명의 치약 조성물 및 염화세틸피리디늄을 함유한 비교예 1 및 2의 치약 조성물이 구취효과가 우수함을 알 수 있었다.
As shown in Table 8 , it was found that the toothpaste composition of Comparative Examples 1 and 2 containing the toothpaste composition of the present invention and cetylpyridinium chloride has an excellent bad breath effect.
상술한 바와 같이, 본 발명의 치약 조성물은 염화세틸피리디늄을 연마용 과립입자에 코팅시켜 적용하므로서, 이를 구강 적용시 세치하는 동안 안정한 상태로 염화세틸피리디늄을 유지시키고, 또한 염화세틸피리디늄의 부착을 높여 효능을 지속시킬 뿐만 아니라 타성분과의 안정성 및 치아의 안전성을 기대할 수 있어 구취제거, 항균작용 및 플라그억제능의 효과가 우수하고, 또한 안정성이 높은 안전한 치약 조성물을 제공할 수 있다. 또한, 본 발명의 치약 조성물은 항염 및 혈액촉진 등의 효능으로 치약 조성물에 복합되는 수종의 생약추출물을 부가함으로써 목적한 효능에 상승적인 활성을 제공한다.As described above, the toothpaste composition of the present invention is coated by applying the cetylpyridinium chloride to the abrasive granules, thereby maintaining the cetylpyridinium chloride in a stable state during the oral application, and also of cetylpyridinium chloride Not only to maintain the efficacy by increasing the adhesion, but also can be expected to be stable with other components and the safety of the teeth can be excellent in the effects of bad breath removal, antibacterial action and plaque suppression, and can provide a safe toothpaste composition with high stability. In addition, the toothpaste composition of the present invention provides synergistic activity to the desired efficacy by adding several kinds of herbal extracts complexed to the toothpaste composition with the efficacy of anti-inflammatory and blood promotion.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030016539A KR100951396B1 (en) | 2003-03-17 | 2003-03-17 | Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030016539A KR100951396B1 (en) | 2003-03-17 | 2003-03-17 | Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040081936A KR20040081936A (en) | 2004-09-23 |
KR100951396B1 true KR100951396B1 (en) | 2010-04-07 |
Family
ID=37365917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030016539A Expired - Lifetime KR100951396B1 (en) | 2003-03-17 | 2003-03-17 | Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100951396B1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100760970B1 (en) | 2004-11-04 | 2007-10-04 | 김종철 | Toothpaste composition containing essential oils |
KR101480690B1 (en) * | 2008-09-03 | 2015-01-09 | (주)아모레퍼시픽 | Oral composition containing natural extract |
KR101583758B1 (en) * | 2015-03-20 | 2016-01-08 | 주식회사 제우메디컬 | Toothpaste composition comprising kiyoseki stone |
KR101583760B1 (en) * | 2015-03-23 | 2016-01-08 | 주식회사 제우메디컬 | Toothpaste composition comprising chondrodite |
KR102230888B1 (en) | 2019-09-03 | 2021-03-22 | 동의대학교 산학협력단 | Toothpaste composition |
CA3164386A1 (en) | 2020-02-18 | 2021-08-26 | Kana Hashimoto | Oral care composition |
IT202100011492A1 (en) | 2021-05-05 | 2022-11-05 | Kalichem Srl | FUNCTIONALIZED BIOMIMETIC HYDROXYAPATITE |
WO2023232570A1 (en) | 2022-05-31 | 2023-12-07 | Unilever Ip Holdings B.V. | Granules of clay-based antimicrobial particles |
WO2023232571A1 (en) | 2022-05-31 | 2023-12-07 | Unilever Ip Holdings B.V. | Spherical granules of clay-based antimicrobial particles |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08245353A (en) * | 1995-03-03 | 1996-09-24 | Lion Corp | Oral cavity composition |
KR20000060197A (en) * | 1999-03-12 | 2000-10-16 | 신창국 | Compositions for cleaning oral cavity |
US6471948B1 (en) | 2000-03-22 | 2002-10-29 | Church & Dwight Co. Inc. | Toothpaste compositions containing cetylpyridinium chloride |
KR20030009578A (en) * | 2001-07-03 | 2003-02-05 | 주식회사 태평양 | Oral composition for inhibiting the halitosis |
-
2003
- 2003-03-17 KR KR1020030016539A patent/KR100951396B1/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08245353A (en) * | 1995-03-03 | 1996-09-24 | Lion Corp | Oral cavity composition |
KR20000060197A (en) * | 1999-03-12 | 2000-10-16 | 신창국 | Compositions for cleaning oral cavity |
US6471948B1 (en) | 2000-03-22 | 2002-10-29 | Church & Dwight Co. Inc. | Toothpaste compositions containing cetylpyridinium chloride |
KR20030009578A (en) * | 2001-07-03 | 2003-02-05 | 주식회사 태평양 | Oral composition for inhibiting the halitosis |
Also Published As
Publication number | Publication date |
---|---|
KR20040081936A (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006320846B2 (en) | Vehicles for oral care with Magnolia Bark Extract | |
TWI477269B (en) | Dentifrice compositions for treating xerostomia | |
RU2526913C2 (en) | Oral care composition | |
TW201622693A (en) | Oral care composition containing vermiculite and zinc citrate | |
US8986659B2 (en) | Diamond, precious and semi-precious dust polishing agent for dental veneers and teeth | |
US20070122357A1 (en) | Dentifrice composition | |
KR100951396B1 (en) | Toothpaste composition excellent in bad breath removal, plaque removal and antibacterial effect | |
CN101316570A (en) | Dentifrice Composition | |
KR20080079776A (en) | Toothpaste composition comprising flower slices of a plant | |
US5316760A (en) | Mouth-care products | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
TWI458500B (en) | Oral health care composition and method | |
JP3336688B2 (en) | Oral composition | |
EP2883532A1 (en) | Diamond dust polishing agent for dental veneers and teeth | |
CN113260346A (en) | Method of inhibiting recruitment of neutrophils to gingival sulcus | |
KR20090091898A (en) | Oral compositions containing luffa cylindrica | |
KR20170120411A (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
WO1989010737A1 (en) | Mouthcare-products | |
KR20170120399A (en) | Composition for prevention or treatment of oral disease comprising Genistein | |
KR20170120416A (en) | Composition for prevention or treatment of oral disease comprising Matairesinol | |
KR20170120414A (en) | Composition for prevention or treatment of oral disease comprising Esculetin | |
KR20170103528A (en) | Composition for prevention or treatment of oral disease comprising Gleditsiae fructus Extract | |
KR20170103486A (en) | Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract | |
KR20170120404A (en) | Composition for prevention or treatment of oral disease comprising 2-methoxycinnamaldehyde |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030317 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20071228 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20030317 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090421 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20091230 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20100330 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20100331 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20121231 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20121231 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131224 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20131224 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20141226 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20151230 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20161229 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180103 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20180103 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181213 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20181213 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20191127 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20201124 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20211119 Start annual number: 13 End annual number: 13 |
|
PC1801 | Expiration of term |
Termination date: 20230917 Termination category: Expiration of duration |